

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1548)**

**VOLUNTARY ANNOUNCEMENT  
INVESTMENT AGREEMENTS WITH SHANDONG SHANGHE  
ECONOMIC DEVELOPMENT ZONE  
MANAGEMENT COMMITTEE**

This is a voluntary announcement made by Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”). The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 15 August 2018, its indirect wholly-owned subsidiary, Bestzyme Biotech HK Limited 香港百斯杰生物科技股份有限公司 (“**BSJ Hong Kong**”), entered into an agreement and a supplemental agreement with Shandong Shanghe Economic Development Zone Management Committee\* 山東商河經濟開發區管理委員會 (the “**Committee**”) in relation to the investment in the production and sale of bio-fermentation products in the economic development zone (the “**Shanghe Economic Development Zone**”) managed by the Committee (collectively, the “**Investment Agreements**”).

Major terms of the Investment Agreements are set out below:

Investment	BSJ Hong Kong or a company established under the relevant laws and regulations of the People’s Republic of China (the “ <b>PRC</b> ”) by BSJ Hong Kong as a foreign investment company (the “ <b>BSJ Hong Kong’s Subsidiary</b> ”), will invest a total of RMB220 million by contributing cash and fixed assets for the construction of factories, office buildings and other ancillary facilities of a project company to be established in the PRC as an indirect subsidiary of the Group (the “ <b>Project Company</b> ”) to produce and sell bio-fermentation products (the “ <b>Investment</b> ”). The Investment will be made in two phases, of which RMB130 million and RMB90 million will be made for Phase I and Phase II, respectively.
------------	---

Land	BSJ Hong Kong or BSJ Hong Kong's Subsidiary will, through the process of bidding invitation, auction or listing* (招 拍 掛) (the " <b>Process</b> "), apply to the Committee for a piece of industrial land of 177 mu located at the Shangnan Industrial Park, Shanghe Economic Development Zone, which can be used for industrial manufacturing (operation), research and development, office facilities and the construction of other essential ancillary facilities only (the " <b>Project Land</b> "). Subject to BSJ Hong Kong or BSJ Hong Kong's Subsidiary successfully bidding for the Project Land through the Process, the Committee shall transfer the Project Land before 30 July 2019.
Constructions	The Project Land will be used for the construction of factories, office buildings and other ancillary facilities for the production and sale of bio-fermentation products (the " <b>Constructions</b> "). The Constructions will be conducted in two phases, where the total area of factories, office buildings and ancillary facilities to be constructed during Phase I and Phase II is approximately 88,044 square meters and 53,626.80 square meters, respectively.
Period of Constructions	The Constructions for each phase will commence within 15 days after BSJ Hong Kong or BSJ Hong Kong's Subsidiary has obtained the relevant permits for construction projects (施工許可證), and each shall last for a period of 24 months.
Government incentive policies	The Project Company will be offered certain incentive policies by the Committee relating to, among others, financial subsidies for the Constructions and talent retention policies, under the Investment Agreements.

## **INFORMATION ON THE COMMITTEE**

The Committee is a governmental organ responsible for administrative approval, economic management and city management of the Shanghe Economic Development Zone of Shandong Province.

## **INFORMATION ON THE GROUP AND BSJ HONG KONG**

The Group is principally engaged in the provision of (i) bio-science services and products, (ii) industrial synthetic biology products, and (iii) precision immune-cell therapy.

BSJ Hong Kong is a limited liability company incorporated in Hong Kong and is an indirect wholly-owned subsidiary of the Company.

By order of the Board  
**Genscript Biotech Corporation**  
**Dr. Zhang Fangliang**  
*Chairman and Chief Executive Officer*

Hong Kong, 15 August 2018

*As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.*

\* *For identification purposes only*